Tuberculosis Screening for Patients on Biologic Medications: A Single-Center Experience and Society Guideline Review, Monroe County, New York, 2018-2021

Overview

Journal J Clin Tuberc Other Mycobact Dis

Date 2024 Jul 18

PMID 39021381

Authors

Tetsuro Maeda

Margaret Connolly

Kelly Thevenet-Morrison

Paul Levy

Mark Utell

Sonal Munsiff

Daniel Croft

Affiliations

Soon will be listed here.

Abstract

Rationale: Biologic medications for immune-mediated inflammatory diseases may increase the risk of tuberculosis (TB) reactivation, but data on screening for TB in low TB prevalence areas are limited.

Objective: To assess the real-world practice patterns of TB screening among prescribers of biologic medications.

Methods: We conducted a retrospective observational study at a single, university-based healthcare facility in a low TB prevalence area. We enrolled adult patients prescribed a biologic medication between October 2018 and December 2021, and collected data on demographics, biologic medications and TB test results. For patients with positive TB tests, further data including prescriber specialty and response to positive tests were obtained. We reviewed pertinent major society guidelines/ consensus statements regarding TB screening among patients treated with biologic medications.

Results: 4,085 patients were included. 3024 (74.0%) had at least one screening TB test and 42 were positive. Among patients treated with tumor necrosis factor-alpha (TNFα) inhibitors, 1779 of 2129 patients (83.6%) underwent TB testing and 25 (1.4%) were positive. Most with positive TB test results were prescribed biologic medication by gastroenterology (11 patients, 26%), dermatology (12, 29%), or rheumatology (15, 36%) providers. 32 (76%) patients had imaging and roughly half were treated for latent TB infection. Biologic medications were temporarily held for 27 patients (67%). Nine out of 13 society guidelines recommend TB screening for TNFα inhibitors but have differing recommendations for other biologic medications.

Conclusions: Significant practice pattern differences in TB screening for patients receiving biologic medications exist. Multiple society guidelines continue to recommend TB screening even for drugs with no known increased risk of TB reactivation.

References

Singh J, Furst D, Bharat A, Curtis J, Kavanaugh A, Kremer J . 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64(5):625-39. PMC: 4081542. DOI: 10.1002/acr.21641. View

Gray J, Reves R, Johnson S, Belknap R . Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis. Clin Infect Dis. 2011; 54(3):e20-3. DOI: 10.1093/cid/cir792. View

Lewinsohn D, Leonard M, LoBue P, Cohn D, Daley C, Desmond E . Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017; 64(2):111-115. PMC: 5504475. DOI: 10.1093/cid/ciw778. View

Menter A, Strober B, Kaplan D, Kivelevitch D, Prater E, Stoff B . Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019; 80(4):1029-1072. DOI: 10.1016/j.jaad.2018.11.057. View

Mancuso J, Mazurek G, Tribble D, Olsen C, Aronson N, Geiter L . Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med. 2011; 185(4):427-34. PMC: 3297098. DOI: 10.1164/rccm.201107-1244OC. View

Baddley J, Cantini F, Goletti D, Gomez-Reino J, Mylonakis E, San-Juan R . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018; 24 Suppl 2:S10-S20. DOI: 10.1016/j.cmi.2017.12.025. View

Bibbins-Domingo K, C Grossman D, Curry S, Bauman L, Davidson K, Epling Jr J . Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016; 316(9):962-9. DOI: 10.1001/jama.2016.11046. View

Rosales-Klintz S, Bruchfeld J, Haas W, Heldal E, Houben R, van Kessel F . Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area. Eur Respir J. 2019; 53(1). DOI: 10.1183/13993003.02077-2018. View

Keane J, Gershon S, Wise R, Kasznica J, Schwieterman W, Siegel J . Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15):1098-104. DOI: 10.1056/NEJMoa011110. View

10.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C . North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019; 81(1):91-101. PMC: 9131892. DOI: 10.1016/j.jaad.2019.02.068. View

11.

Fragoulis G, Nikiphorou E, Dey M, Zhao S, Courvoisier D, Arnaud L . 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2022; 82(6):742-753. DOI: 10.1136/ard-2022-223335. View

12.

Lichtenstein G, Loftus E, Isaacs K, Regueiro M, Gerson L, Sands B . ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018; 113(4):481-517. DOI: 10.1038/ajg.2018.27. View

13.

Ward M, Deodhar A, Gensler L, Dubreuil M, Yu D, Khan M . 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019; 71(10):1599-1613. PMC: 6764882. DOI: 10.1002/art.41042. View

14.

Park C, Park J, Jung Y . Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Pers Med. 2022; 12(3). PMC: 8953543. DOI: 10.3390/jpm12030507. View

15.

Ya J, Khanna U, Havele S, Fernandez A . Utility of repeat latent tuberculosis testing with the QuantiFERON-TB Gold test in patients with psoriasis treated with tumour necrosis factor-α inhibitors at a single U.S. institution. Br J Dermatol. 2019; 182(3):800-802. DOI: 10.1111/bjd.18461. View

16.

Reinwald M, Silva J, Mueller N, Fortun J, Garzoni C, de Fijter J . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018; 24 Suppl 2:S53-S70. DOI: 10.1016/j.cmi.2018.02.009. View

17.

Colombel J, Sands B, Rutgeerts P, Sandborn W, Danese S, DHaens G . The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2016; 66(5):839-851. PMC: 5531223. DOI: 10.1136/gutjnl-2015-311079. View

18.

Dumaine C, Bekkar S, Belot A, Cabrera N, Malik S, Von Scheven A . Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte. Joint Bone Spine. 2019; 87(1):49-55. DOI: 10.1016/j.jbspin.2019.07.011. View

19.

Winthrop K, Mariette X, Silva J, Benamu E, Calabrese L, Dumusc A . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins,.... Clin Microbiol Infect. 2018; 24 Suppl 2:S21-S40. DOI: 10.1016/j.cmi.2018.02.002. View

20.

Chung S, Langford C, Maz M, Abril A, Gorelik M, Guyatt G . 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021; 73(8):1366-1383. DOI: 10.1002/art.41773. View